Australia markets open in 3 hours 32 minutes

Cronos Group Inc. (CRON)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.0100+0.0400 (+1.35%)
At close: 04:00PM EDT
3.0400 +0.03 (+1.00%)
After hours: 04:27PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.9700
Open2.9500
Bid2.9800 x 21500
Ask3.0400 x 1000
Day's range2.9400 - 3.0600
52-week range2.5700 - 8.5950
Volume1,771,375
Avg. volume1,915,163
Market cap1.151B
Beta (5Y monthly)1.51
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Cronos Group Partners with Geocann to Leverage VESIsorb® Delivery Technology for Faster Absorption

    TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) is pleased to announce the launch of the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the advanced VESIsorb® delivery system. This technology provides better bioavailability and faster absorption. VESIsorb® formulations have set the industry benchmark in peer-reviewed published studies, delivering superior pharmacokinetic perf

  • GlobeNewswire

    Cronos Group Inc. Announces Results of 2022 Annual Meeting of Shareholders

    TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announces that at its Annual Meeting of Shareholders held on June 23, 2022 (the “Meeting”) shareholders voting in person or by proxy held in total 265,763,587 common shares of the Company, representing 70.76% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company’s proxy statement dated April 29, 2022 (the “Proxy St

  • PR Newswire

    Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone

    Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) ("Ginkgo"), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo's platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid